Hikal Limited has made the audio recording of its earnings group conference call available to investors and stakeholders. The discussion covered financial performance and operational updates for the quarter ended June 30, 2026. This release ensures transparency and provides detailed insights into the company’s recent business activities beyond the written filing.

The conference call was held on Thursday, August 06, 2026, at 5:00 PM (IST). In accordance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Hikal submitted this disclosure to both the Bombay Stock Exchange and the National Stock Exchange of India Limited. The audio file is hosted on the company’s official website for public access.

Call Details

The following table outlines the key logistical details of the earnings communication:

This disclosure follows an earlier letter dated July 30, 2026, which likely announced the schedule or preliminary results. The availability of the recording allows investors to hear management’s commentary directly, offering context for the reported figures.

Regulatory Compliance

Hikal Limited remains compliant with SEBI’s listing obligations. The submission was authorized by Rajasekhar Reddy Chintakindi, the Company Secretary & Compliance Officer. His digital signature confirms the authenticity of the disclosure dated August 06, 2026. The company continues to adhere to standard corporate governance practices regarding investor communications.

What the Numbers Show

While this specific filing only confirms the availability of the audio recording, it signals that the Q2FY26 results have been formally presented to the market. Investors are encouraged to review the recording for management’s perspective on revenue drivers, cost structures, and future outlook. The lack of specific financial metrics in this notice means the primary value lies in the qualitative insights provided during the live discussion.

Hikal Ltd reported consolidated revenue of ₹403 crore for the quarter ended June 30, 2026, marking a 6.2% year-on-year growth despite geopolitical and macroeconomic headwinds. The company’s EBITDA expanded significantly by 47.4% to ₹37 crore, driven by an improvement in margins that widened by 260 basis points to 9.2%. However, Hikal recorded a net loss of ₹7 crore for the period, compared to a loss of ₹22 crore in the same quarter last year. The results reflect a transitional phase as the company moves from regulatory-led disruption toward growth, with management citing improving customer demand and execution-led performance.

The pharmaceutical business was the primary growth driver, delivering revenue of ₹233 crore, a 15.2% increase year-on-year. This segment accounted for 58% of total revenue, up from 53% in Q1FY26. The recovery was supported by strengthening demand in regulated markets and improved customer offtake across own products and CDMO operations. Conversely, the crop-protection business saw revenue decline to ₹170 crore from ₹178 crore in the previous year’s corresponding quarter, contributing 42% to the total mix. While own products delivered volume-led growth in domestic markets, CDMO demand remained subdued due to customer inventory adjustments and higher input costs stemming from geopolitical developments.

Financial Performance Overview

Jai Hiremath, Executive Chairman of Hikal Ltd., noted that Q1FY27 represented a slower start as the company transitions from regulatory remediation to growth. He highlighted that significant time and resources were invested in compliance with US FDA recommendations, which temporarily slowed sales in the pharmaceutical business due to planned plant shutdowns. The company is now in the penultimate stage of its remediation plan, with a reinspection expected during the current fiscal year. Hiremath expressed confidence in capitalizing on the CDMO pipeline and specialty APIs in oncology, CNS, gastroenterology, and complex chemistries.

What the Numbers Show

The divergence between revenue growth and net profitability highlights the operational leverage being regained by Hikal. While revenue grew modestly at 6.2%, EBITDA nearly doubled year-on-year, indicating that fixed costs are being absorbed more efficiently as volumes recover. However, the persistence of a net loss, albeit reduced from ₹22 crore to ₹7 crore, suggests that non-operating expenses or one-time charges may still be impacting the bottom line. The shift in revenue mix towards pharmaceuticals (58%) from crop protection (42%) also signals a strategic pivot towards higher-margin regulated markets, supported by an increased DMF filing trajectory of 5–6 filings annually compared to 2–3 historically.

Looking ahead, management expects business momentum to strengthen progressively through FY27. Key initiatives include the commissioning of a new cGMP pilot plant in Pune to enhance pharmaceutical development capabilities and the commercialization of the Personal Care business in July 2026. Additionally, Hikal received a Gold rating from EcoVadis, placing it in the top 5% of companies globally, which reinforces its positioning among global life sciences partners. The company remains focused on expanding CDMO opportunities and achieving operational excellence to drive stepwise recovery in revenues and profitability.